Home » Topics » BioWorld Science

BioWorld Science
RSS

Dosing begins in phase II trial of onapristone and anastrozole in endometrial cancer

May 13, 2021

OCS-02 shows safety and efficacy in phase II study in patients with acute anterior uveitis

May 13, 2021

HU-6 enters phase II development as potential treatment of NASH

May 13, 2021

Clene Nanomedicine presents preliminary phase II data for CNM-Au8 in ALS

May 13, 2021

Preclinical characterization of novel 3CL(pro) inhibitors against COVID-19

May 13, 2021

China's NMPA issues clinical trial approval for JS-103 for gout

May 13, 2021

Mabwell initiates first-in-human study of 9MW-1411

May 13, 2021

Inovio reports preclinical data on next-generation pan-COVID-19 vaccine candidate INO-4802

May 13, 2021

Mitsubishi Tanabe discontinues development of MT-5745 for ulcerative colitis

May 13, 2021

New phase II trial evaluates CBP-201 for moderate to severe persistent asthma

May 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...